Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials-Reference-Cited by-同舟云学术

Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials

Published:2016-09-22 Issue:2 Volume:28 Page:174-181
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Roule Vincent¹,Agueznai Moaad¹,Sabatier Rémi¹,Blanchart Katrien¹,Lemaître Adrien¹,Ardouin Pierre¹,Collet Jean-Philippe²,Milliez Paul¹,Montalescot Gilles²,Beygui Farzin¹²

Affiliation:

1. Department of Cardiology, Caen University Hospital, Caen, France

2. ACTION Academic Group, Institut de Cardiologie, Pitié-Salpétrière University Hospital, Paris, France

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2016.1218453

Reference30 articles.

1. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

2. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

3. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study;European Heart Journal - Cardiovascular Pharmacotherapy;2024-04-11

2. Thrombus containing lesions strategies during primary percutaneous coronary interventions in ST-segment elevation myocardial infarction: insights from ORPKI National Registry;Journal of Thrombosis and Thrombolysis;2023-04-24

3. In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors;Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology;2022-07-13

4. Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants after Percutaneous Coronary Intervention;Interventional Cardiology;2022-05-06

5. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data;The Anatolian Journal of Cardiology;2021-10-06